Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and othersLed ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Along the eastern shore of Hudson Bay in Canada’s northeastern province of Quebec, near the Inuit municipality of Inukjuak, ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.